82 related articles for article (PubMed ID: 27646721)
1. Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance.
Dasgupta H; Mukherjee N; Islam S; Bhattacharya R; Alam N; Roy A; Roychoudhury S; Biswas J; Panda CK
Future Oncol; 2017 Jan; 13(2):159-174. PubMed ID: 27646721
[TBL] [Abstract][Full Text] [Related]
2. Induction of HRR genes and inhibition of DNMT1 is associated with anthracycline anti-tumor antibiotic-tolerant breast carcinoma cells.
Dasgupta H; Islam MS; Alam N; Roy A; Roychoudhury S; Panda CK
Mol Cell Biochem; 2019 Mar; 453(1-2):163-178. PubMed ID: 30178275
[TBL] [Abstract][Full Text] [Related]
3. Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.
Dasgupta H; Islam S; Alam N; Roy A; Roychoudhury S; Panda CK
J Surg Oncol; 2019 Jan; 119(1):88-100. PubMed ID: 30481381
[TBL] [Abstract][Full Text] [Related]
4. Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma.
Sinha S; Singh RK; Alam N; Roy A; Roychoudhury S; Panda CK
Mol Cancer; 2008 Nov; 7():84. PubMed ID: 18990233
[TBL] [Abstract][Full Text] [Related]
5. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer.
André S; P Nunes S; Silva F; Henrique R; Félix A; Jerónimo C
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32295201
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
Alshareeda AT; Negm OH; Albarakati N; Green AR; Nolan C; Sultana R; Madhusudan S; Benhasouna A; Tighe P; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2013 Jun; 139(2):301-10. PubMed ID: 23624778
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Watanabe Y; Maeda I; Oikawa R; Wu W; Tsuchiya K; Miyoshi Y; Itoh F; Tsugawa K; Ohta T
Genes Cells; 2013 Dec; 18(12):1120-30. PubMed ID: 24581343
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
10. Frequent alterations of LOH11CR2A, PIG8 and CHEK1 genes at chromosomal 11q24.1-24.2 region in breast carcinoma: clinical and prognostic implications.
Sinha S; Singh RK; Bhattacharya N; Mukherjee N; Ghosh S; Alam N; Roy A; Roychoudhury S; Panda CK
Mol Oncol; 2011 Oct; 5(5):454-64. PubMed ID: 21803008
[TBL] [Abstract][Full Text] [Related]
11. Subtype-specific alterations of the Wnt signaling pathway in breast cancer: clinical and prognostic significance.
Mukherjee N; Bhattacharya N; Alam N; Roy A; Roychoudhury S; Panda CK
Cancer Sci; 2012 Feb; 103(2):210-20. PubMed ID: 22026417
[TBL] [Abstract][Full Text] [Related]
12. Frequent alterations of MCPH1 and ATM are associated with primary breast carcinoma: clinical and prognostic implications.
Bhattacharya N; Mukherjee N; Singh RK; Sinha S; Alam N; Roy A; Roychoudhury S; Panda CK
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S424-32. PubMed ID: 23117476
[TBL] [Abstract][Full Text] [Related]
13. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
15. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
[TBL] [Abstract][Full Text] [Related]
16. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
[TBL] [Abstract][Full Text] [Related]
17. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
[TBL] [Abstract][Full Text] [Related]
18. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
[TBL] [Abstract][Full Text] [Related]
20. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer.
Fiegl H; Jones A; Hauser-Kronberger C; Hutarew G; Reitsamer R; Jones RL; Dowsett M; Mueller-Holzner E; Windbichler G; Daxenbichler G; Goebel G; Ensinger C; Jacobs I; Widschwendter M
Clin Cancer Res; 2008 Jun; 14(11):3494-502. PubMed ID: 18519782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
